青光眼及激素反应者接受地塞米松植入剂后的眼压变化
该回顾性研究在印度三级医疗中心纳入815例接受地塞米松(DEX)植入剂的患者,其中非青光眼组767例、青光眼转诊组48例。两组的基线眼压与随访眼压差异均有统计学意义(P < 0.001),且各次随访间眼压变化也有统计学意义(P < 0.001)。眼压升高组中46.43%在1周随访时眼压升幅最大,39%在2周随访时升幅最大,78.6%使用1种抗青光眼药物即可控制眼压。
要点
- DEX植入剂后眼压升高见于前2周,可用局部抗青光眼药物控制。
- 眼压升高组中46.43%在1周随访时眼压升幅最大,39%在2周随访时升幅最大。
- 眼压升高组中78.6%使用1种抗青光眼药物即可控制眼压。
核心结论
- DEX植入剂后眼压升高见于前2周,可用局部抗青光眼药物控制;作者认为通过密切的早期随访监测眼压和及时的医疗干预,青光眼患者可以接受DEX植入。
研究设计与样本
- 回顾性研究,在印度一家三级医疗中心纳入接受DEX植入剂的患者815例,其中非青光眼组767例、青光眼转诊组48例。
主要发现
- 研究参与者总体平均(标准差)年龄为56.3(标准差=12.6)岁。
- 非青光眼组和青光眼转诊组的基线眼压与注射后随访眼压总体平均(标准差)差异均有统计学意义(P < 0.001)。
- DEX植入后各次随访间眼压测量差异在非青光眼组(P < 0.001)和青光眼转诊组(P < 0.001)均有统计学意义。
- 眼压升高组中46.43%在1周随访时眼压升幅最大,39%在2周随访时升幅最大。
- 眼压升高组中78.6%使用1种抗青光眼药物即可控制眼压。
临床怎么用
- 作者认为通过密切的早期随访监测眼压和及时的医疗干预,青光眼患者可以接受DEX植入。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the changes in intraocular pressure (IOP) after dexamethasone (DEX) implant in patients with glaucoma or history of steroid responders. METHODS: A retrospective study of patients who received DEX implant was conducted in a tertiary care center in India. Demographic details and IOP measurements at preinjection and postinjection were collected. The proportion of patients with and without IOP rise after DEX implant was noted, and the number of antiglaucoma medications to control the IOP was analyzed. The changes in IOP were also compared in the group with no glaucoma/steroid responder. RESULTS: A total of 815 patients, 767 patients in the nonglaucoma group and 48 patients in the glaucoma referral group, who underwent DEX implant were included in this study. The overall mean (SD) age of study participants was 56.3 (SD = 12.6) years. The overall mean (SD) IOP at baseline and at follow-up after injection for both nonglaucoma and glaucoma referral groups was found to be significant (P < 0.001). The differences in IOP measurements across follow-ups after DEX implant were found to be significant in both nonglaucoma (P < 0.001) and glaucoma referral groups (P < 0.001). Among the study patients in the IOP-rise group, 46.43% had maximum IOP rise in 1-week follow-up and 39% in 2-week follow-up, where 78.6% showed IOP controlled with 1 antiglaucoma medication. CONCLUSION: The rise in IOP after DEX implant was noted within first 2 weeks, which can be managed with topical antiglaucoma medications. Hence, with a close early follow-up monitoring of IOP, and timely medical intervention, DEX implant can be performed in patients with glaucoma.
引用
- Srinivasan R, Sharma U, George R, et al. INTRAOCULAR PRESSURE CHANGES AFTER DEXAMETHASONE IMPLANT IN PATIENTS WITH GLAUCOMA AND STEROID RESPONDERS. Retina. 2019. PMID: 29095355. doi:10.1097/IAE.0000000000001924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。